QBie™ Spotlight: Nexeon MedSystems Inc. (OTCQB: NXNN)
What does Nexeon MedSystems do?
Will Rosellini (Chairman & CEO – OTCQB: NXNN): “Nexeon Medsystems, Inc. is a global medical device company focused on providing innovative neurostimulation products that improve the quality-of-life of patients suffering from debilitating neurological diseases. Nexeon has developed and commercialized a neurostimulation system that can be utilized to treat a variety of neurological diseases.”
What is the next big goal NXXN is trying to accomplish/what should we keep an eye out for?
Will Rosellini: “We anticipate several events on the horizon for Nexeon. Primarily, the company has previously received a CE Mark for NNS and expects to initiate commercial activities in 2Q18 following a re-issued CE Mark. Additionally, Nexeon management has indicated that the Company has access to nearly $3.9mn in non-dilutive funding in the form of subsidies for the development of other proprietary technologies. Finally, the Company has entered into the second phase of a supply and manufacturing agreement with a significant bioelectronics company to provide Nexeon’s neurostimulation platform for pre-clinical and clinical research. Management is optimistic that the relationship has the potential to become a source of capital either through licensing or research and development funding in the future.”
Why did you join the OTCQB/go public?
Will Rosellini: “Our objectives for going public are multifold. 1) Real market response in pricing. We are aware that this is a double edged sword, but we are confident that this vehicle will facilitate a more accurate valuation than can be seen in the private company environment. Also, with the rapid advancements in this sector, stakeholders benefit most when activity is achieved in a liquid stock. 2) Transparency. Our board values the trust our stakeholders put into our strategic decisions. We recognize that having full financial transparency via SEC reporting provides the information both existing and potential stakeholders would need and want when evaluating our investment merits. 3) Time horizon to exit. While we aim to attract stakeholders who understand our long term vision, there is mutual benefit in broadening the investor spectrum so that interested parties can participate in our misison for a more flexible window instead of being locked into the alternative, privately held company.
Ultimately, we have no desire to raise irresponsible levels of capital via venture funds or by other means. We are executing upon a capital-conscious strategy, and we are committed to proving the business at each stage. We are focused on getting to profitability and optimizing for return on equity. It’s certainly not the easy way in regards to capital, but we are a company that plans to be a big player in the future of this space, so we’ve been steadfast in our lean operations so that we continue to be a business that people want to invest in.”
How can members of the microcap community help you?
Will Rosellini: “Nexeon is in the process raising capital in the form of issuing a $3mn private placement with price protection and 50% warrant coverage.”
Will Rosellini, Chairman & CEO of Nexeon MedSystems can be reached via email at: email@example.com
QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.
Disclaimer/Forward Looking Statements:
This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.